Kodiak Sciences (KOD) Price & Analysis

Compare

382 Followers

KOD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.92 - $11.60

Previous CloseN/A

Volume87.32K

Average Volume (3M)689.45K

Market Cap

$477.51M

Enterprise Value$257.91M

Total Cash (Recent Filing)$104.17M

Total Debt (Recent Filing)$65.21M

Price to Earnings (P/E)―

Beta3.48

Next Earnings

Nov 12, 2025

EPS Estimate

-1.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.03

Shares Outstanding52,821,690

10 Day Avg. Volume637,551

30 Day Avg. Volume689,451

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.54

Enterprise Value/Revenue9.68

Enterprise Value/Gross Profit-2.63K

Enterprise Value/Ebitda-1.36

Forecast

1Y Price Target

$9.00

Price Target Upside5.02% Upside

Rating ConsensusModerate Sell

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsKOD's enhanced formulations and improved study designs in Phase III trials aim to increase the probability of success.

Financial StabilityKOD ended with $168M in cash, which is projected to support them through the upcoming years, indicating a stable financial position.

Research And DevelopmentKOD plans to host an R&D day and share promising Phase I data for KSI-101, which could lead to further advancements in their drug development.

Bears Say

Clinical Trial SetbacksDe-risking of the enhanced formulation design remains critical due to former Phase 3 GLEAM and GLIMMER trial failures in diabetic macular edema and unexpected cataract adverse events over time for tarcocimab.

Confidence In FormulationThe Phase 2b/3 DAZZLE trial failure in wet AMD affects confidence in the current formulation development.

Platform ValidationReformulated conjugated tarcocimab and KSI-501 validation is not expected until 2026, leaving analysts awaiting pivotal confirmation.

Kodiak Sciences News

Kodiak Sciences price target raised to $7 from $4 at Barclays

Barclays raised the firm’s price target on Kodiak Sciences (KOD) to $7 from $4 and keeps an Underweight...

21d ago

KOD

Kodiak Sciences upgraded to Neutral from Underweight at JPMorgan

JPMorgan upgraded Kodiak Sciences (KOD) to Neutral from Underweight with a $15 price target The firm says the...

21d ago

KOD

Kodiak Sciences reports Q2 EPS ($1.03), consensus ($1.05)

Ended Q2 with $104.2M of cash and cash equivalents, believes current cash will support current and planned operations...

22d ago

KOD

Kodiak Sciences Reports Q2 2025 Financial Results and Clinical Progress

Kodiak Sciences ( ($KOD) ) has released its Q2 earnings. Here is a breakdown of the information Kodiak...

21d ago

KOD

Cautious Hold Rating for Kodiak Sciences Amid Promising Early Data and Awaited Platform Validation

Analyst Matthew Caufield of H.C. Wainwright reiterated a Hold rating on Kodiak Sciences, retaining the price target of...

2M ago

KOD

Kodiak Sciences Holds 2025 Annual Stockholders Meeting

Kodiak Sciences ( ($KOD) ) has issued an update. On June 2, 2025, Kodiak Sciences Inc. held its...

3M ago

KOD

Cautious Hold Rating on Kodiak Sciences Amid Strategic Developments and Past Trial Challenges

H.C. Wainwright analyst Matthew Caufield reiterated a Hold rating on Kodiak Sciences (KOD – Research Report) today and...

4M ago

KOD

Kodiak Sciences reports Q1 EPS ($1.09), consensus (87c)

“In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing...

4M ago

KOD

Kodiak Sciences: Hold Rating Amidst Strategic Advances and Long-term Catalysts

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Hold rating on Kodiak Sciences (KOD – Research Report)....

5M ago

KOD

Promising Outlook for Kodiak Sciences: Buy Rating Backed by Upcoming R&D Day and Strategic Advancements

In a report released yesterday, Michael Yee from Jefferies maintained a Buy rating on Kodiak Sciences (KOD –...

5M ago

KOD

Kodiak Sciences Advances Retinal Therapies with Promising Pipeline

Kodiak Sciences ( ($KOD) ) has released its Q4 earnings. Here is a breakdown of the information Kodiak...

5M ago

KOD

Kodiak Sciences reports Q4 EPS 84c, consensus (86c)

Ended Q4 with $168.1M of cash and cash equivalents and believes current cash will support current and planned...

5M ago

KOD

KOD Upcoming Earnings Report: What to Expect?

Kodiak Sciences (KOD) is scheduled to report 4th quarter earnings on 03/27/2025. Regarding Q4 estimates, Wall Street analysts...

5M ago

KOD

Kodiak Sciences completes enrollment in GLOW2 Phase 3 trial

Kodiak Sciences (KOD) announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab...

6M ago

KOD

KOD FAQ

What was Kodiak Sciences Inc’s price range in the past 12 months?

Kodiak Sciences Inc lowest stock price was $1.92 and its highest was $11.60 in the past 12 months.

What is Kodiak Sciences Inc’s market cap?

Kodiak Sciences Inc’s market cap is $477.51M.

When is Kodiak Sciences Inc’s upcoming earnings report date?

Kodiak Sciences Inc’s upcoming earnings report date is Nov 12, 2025 which is in 69 days.

How were Kodiak Sciences Inc’s earnings last quarter?

Kodiak Sciences Inc released its earnings results on Aug 13, 2025. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.068 by $0.038.

Is Kodiak Sciences Inc overvalued?

According to Wall Street analysts Kodiak Sciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kodiak Sciences Inc pay dividends?

Kodiak Sciences Inc does not currently pay dividends.

What is Kodiak Sciences Inc’s EPS estimate?

Kodiak Sciences Inc’s EPS estimate is -1.05.

How many shares outstanding does Kodiak Sciences Inc have?

Kodiak Sciences Inc has 52,821,690 shares outstanding.

What happened to Kodiak Sciences Inc’s price movement after its last earnings report?

Kodiak Sciences Inc reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.068. Following the earnings report the stock price went up 16.473%.

Which hedge fund is a major shareholder of Kodiak Sciences Inc?

Currently, no hedge funds are holding shares in KOD

Kodiak Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-140.33%

Trailing 12-Months

Asset Growth

-36.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kodiak Sciences Inc

Kodiak Sciences Inc. (KOD) is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of retinal diseases. The company is headquartered in Palo Alto, California, and operates within the biotechnology and pharmaceutical sectors. Its core product candidate is KSI-301, an investigational therapy designed to improve outcomes for patients with retinal vascular diseases such as wet age-related macular degeneration and diabetic eye diseases.

Kodiak Sciences (KOD) Earnings & Revenues

Historic Earnings Reports

KOD Stock 12 Month Forecast

Average Price Target

$9.00

▲(5.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","4.75":"$4.75","8.5":"$8.5","12.25":"$12.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.75,8.5,12.25,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,7.292307692307693,7.934615384615385,8.576923076923077,9.21923076923077,9.861538461538462,10.503846153846155,11.146153846153846,11.788461538461538,12.430769230769231,13.073076923076922,13.715384615384615,14.357692307692307,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,6.830769230769231,7.0115384615384615,7.1923076923076925,7.3730769230769235,7.553846153846154,7.734615384615385,7.915384615384616,8.096153846153847,8.276923076923078,8.457692307692309,8.638461538461538,8.819230769230769,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,6.523076923076923,6.3961538461538465,6.269230769230769,6.142307692307693,6.015384615384615,5.888461538461539,5.7615384615384615,5.634615384615385,5.507692307692308,5.380769230769231,5.253846153846154,5.126923076923077,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.01,"date":1709251200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.45,"date":1711929600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.53,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.89,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.95,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.49,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >